The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Wentworth Kory James since 2018.
This trader's CIK number is 1725663.
At the time of last reporting, Wentworth Kory James was the Chief Financial Officer of Entrada Therapeutics, Inc.. (stock ticker symbol TRDA).
Also see all insider trading activities at Entrada Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | TRDA | 0 | $0 | 1,784 | $19,035 | 11,134 | $23,381 |
| 2024 | TRDA | 0 | $0 | 23,676 | $416,908 | 21,000 | $44,100 |
| 2023 | TRDA | 0 | $0 | 42,697 | $671,084 | 48,790 | $102,457 |
| 2022 | TRDA | 0 | $0 | 12,455 | $163,867 | 6,472 | $13,590 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | BLUE | 0 | $0 | 1,055 | $74,680 | 0 | $0 |
| 2019 | BLUE | 0 | $0 | 926 | $109,858 | 0 | $0 |
| 2018 | BLUE | 0 | $0 | 388 | $39,983 | 0 | $0 |
1. Entrada Therapeutics, Inc. (TRDA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-03 | TRDA | Option Ex | 11,134 | 2.10 | 23,381 |
| 2025-03-17 | TRDA | Sale | 1,784 | 10.67 | 19,035 |
| 2024-11-29 | TRDA | Option Ex | 1,000 | 2.10 | 2,100 |
| 2024-12-02 | TRDA | Option Ex | 5,000 | 2.10 | 10,500 |
| 2024-11-29 | TRDA | Sale | 1,000 | 19.97 | 19,970 |
| 2024-12-02 | TRDA | Sale | 5,000 | 20.00 | 99,980 |
| 2024-11-11 | TRDA | Option Ex | 6,000 | 2.10 | 12,600 |
| 2024-11-11 | TRDA | Sale | 8,637 | 19.98 | 172,558 |
| 2024-09-09 | TRDA | Sale | 3,195 | 14.97 | 47,832 |
| 2024-07-08 | TRDA | Sale | 1,758 | 14.95 | 26,282 |
| 2024-03-15 | TRDA | Option Ex | 9,000 | 2.10 | 18,900 |
| 2024-03-06 | TRDA | Sale | 4,086 | 12.31 | 50,286 |
| 2023-12-26 | TRDA | Option Ex | 94 | 2.10 | 197 |
| 2023-12-22 | TRDA | Sale | 10,206 | 15.86 | 161,897 |
| 2023-12-21 | TRDA | Sale | 2,200 | 15.07 | 33,154 |
| 2023-12-22 | TRDA | Option Ex | 10,206 | 2.10 | 21,432 |
| 2023-12-21 | TRDA | Option Ex | 2,200 | 2.10 | 4,620 |
| 2023-12-26 | TRDA | Sale | 94 | 16.67 | 1,566 |
| 2023-09-06 | TRDA | Sale | 950 | 13.74 | 13,053 |
| 2023-07-11 | TRDA | Sale | 3,884 | 18.00 | 69,904 |
| 2023-07-10 | TRDA | Sale | 6,116 | 17.98 | 109,959 |
| 2023-07-11 | TRDA | Option Ex | 3,884 | 2.10 | 8,156 |
| 2023-07-10 | TRDA | Option Ex | 6,116 | 2.10 | 12,843 |
| 2023-06-29 | TRDA | Option Ex | 8,790 | 2.10 | 18,459 |
| 2023-06-21 | TRDA | Option Ex | 17,500 | 2.10 | 36,750 |
| 2023-06-21 | TRDA | Sale | 17,500 | 15.01 | 262,605 |
| 2023-03-02 | TRDA | Sale | 1,747 | 10.85 | 18,946 |
| 2022-11-16 | TRDA | Sale | 200 | 18.10 | 3,620 |
| 2022-11-16 | TRDA | Option Ex | 200 | 2.10 | 420 |
| 2022-08-23 | TRDA | Option Ex | 1,403 | 2.10 | 2,946 |
| 2022-08-22 | TRDA | Option Ex | 117 | 2.10 | 245 |
| 2022-08-19 | TRDA | Sale | 8,529 | 13.08 | 111,533 |
| 2022-08-19 | TRDA | Option Ex | 4,452 | 2.10 | 9,349 |
| 2022-08-23 | TRDA | Sale | 2,909 | 13.09 | 38,078 |
| 2022-08-22 | TRDA | Sale | 217 | 13.01 | 2,822 |
| 2022-08-18 | TRDA | Sale | 200 | 13.00 | 2,600 |
| 2022-08-17 | TRDA | Sale | 200 | 13.07 | 2,614 |
| 2022-08-18 | TRDA | Option Ex | 100 | 2.10 | 210 |
| 2022-08-16 | TRDA | Sale | 200 | 13.00 | 2,600 |
| 2022-08-17 | TRDA | Option Ex | 100 | 2.10 | 210 |
| 2022-08-16 | TRDA | Option Ex | 100 | 2.10 | 210 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-08-03 | BLUE | Sale | 82 | 61.00 | 5,002 |
| 2020-07-20 | BLUE | Sale | 596 | 66.38 | 39,562 |
| 2020-06-04 | BLUE | Sale | 154 | 65.28 | 10,053 |
| 2020-01-07 | BLUE | Sale | 223 | 89.97 | 20,063 |
| 2019-12-19 | BLUE | Sale | 397 | 92.59 | 36,758 |
| 2019-06-05 | BLUE | Sale | 61 | 128.48 | 7,837 |
| 2019-02-28 | BLUE | Sale | 51 | 151.71 | 7,737 |
| 2019-02-25 | BLUE | Sale | 208 | 150.00 | 31,200 |
| 2019-01-28 | BLUE | Sale | 209 | 125.96 | 26,326 |
| 2018-12-19 | BLUE | Sale | 388 | 103.05 | 39,983 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Wentworth Kory James (Chief Financial Officer of Entrada Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.